Pancreatic Neoplasms

"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

Descriptor ID	D010190
MeSH Number(s)	C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
Concept/Terms	Pancreatic Neoplasms Pancreatic Neoplasms Neoplasm, Pancreatic Pancreatic Neoplasm Pancreas Neoplasms Neoplasm, Pancreas Neoplasms, Pancreas Pancreas Neoplasm Neoplasms, Pancreatic Cancer of Pancreas Cancer of Pancreas Pancreas Cancers Pancreas Cancer Cancer, Pancreas Cancers, Pancreas Pancreatic Cancer Cancer, Pancreatic Cancers, Pancreatic Pancreatic Cancers Cancer of the Pancreas

Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Digestive System Neoplasms [C04.588.274]
Pancreatic Neoplasms [C04.588.274.761]
Endocrine Gland Neoplasms [C04.588.322]
Pancreatic Neoplasms [C04.588.322.475]
Digestive System Diseases [C06]
Digestive System Neoplasms [C06.301]
Pancreatic Neoplasms [C06.301.761]
Pancreatic Diseases [C06.689]
Pancreatic Neoplasms [C06.689.667]
Endocrine System Diseases [C19]
Endocrine Gland Neoplasms [C19.344]
Pancreatic Neoplasms [C19.344.421]

Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.

Bar chart showing 175 publications over 23 distinct years, with a maximum of 14 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	1	0	1
2004	3	2	5
2005	1	3	4
2006	7	1	8
2007	6	3	9
2008	3	0	3
2009	4	0	4
2010	5	0	5
2011	7	0	7
2012	5	0	5
2013	11	0	11
2014	12	0	12
2015	11	0	11
2016	9	2	11
2017	6	0	6
2018	5	0	5
2019	12	1	13
2020	11	0	11
2021	5	0	5
2022	7	0	7
2023	14	0	14
2024	11	0	11
2025	7	0	7

Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.

Umemura K, Akiyama Y, Shimada S, Hatano M, Kono A, Yasukawa K, Kamachi A, Igarashi Y, Tsukihara S, Tanji Y, Morimoto K, Nara A, Yamane M, Akahoshi K, Ono H, Shimizu A, Soejima Y, Tanabe M, Ban D, Tanaka S. PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Mol Cancer Res. 2025 Oct 02; 23(10):844-858.

View in: PubMed
Han S, Paik A, Acoba J, Wilkens LR, Le Marchand L, Huang BZ. Risk Factor Profiles and Elevated Incidence of Pancreatic Cancer in Native Hawaiians. Am J Gastroenterol. 2026 Jan 01; 121(1):274-276.

View in: PubMed
Jung HN, Huh JH, Roh E, Kim BJ, Lee M, Kim JK, Kim JH, Han B, Han KD, Kang JG, Lee SJ, Ihm SH. Risk of pancreatic cancer according to glycemic status in nonalcoholic fatty liver disease: a nationwide cohort study. Sci Rep. 2025 Jul 02; 15(1):23308.

View in: PubMed
Sharma S, Singh R, Kant S, Mishra MK. Integrating AI/ML and multi-omics approaches to investigate the role of TNFRSF10A/TRAILR1 and its potential targets in pancreatic cancer. Comput Biol Med. 2025 Jul; 193:110432.

View in: PubMed
Yi S, Noh K, Kim H, Jung E, Kim S, Lee J, Guk K, Choi J, Lim EK, Kim S, Park H, Lim JH, Jung CR, Kang T, Jung J. Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation. Mol Cancer. 2025 Apr 24; 24(1):124.

View in: PubMed
Karim M, Hasan MM, Kim SH, Azam Z, Wahab R, Islam T, Alam F, Kim YJ, Bae DJ, Roy S, Grippo P, Bishehsari F, Choi JU, Al-Hilal TA. Stromal fibrin shapes immune infiltration landscape of pancreatic ductal adenocarcinoma. Biomaterials. 2025 Sep; 320:123280.

View in: PubMed
Riner AN, Velazquez-Villarreal EI, Rajpara S, Qian J, Jin Y, Loza D, Akki A, Herremans KM, Raj R, Williams TM, Merchant N, George TJ, Hughes SJ, Stern MC, Reams R, Redda K, Wilkie DJ, Odedina FT, Chamala S, Han B, Agyare E, Craig DW, Carpten JD, Trevino JG. Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients. Pancreas. 2025 Mar 01; 54(3):e171-e178.

View in: PubMed
Irfan A, McElroy KE, Zheng-Pywell R, Gillis A, Reddy S, Yates C, Chen H, Rose JB. NET guidelines for white patients may not fit Asian patients. Am J Surg. 2025 Feb; 240:116116.

View in: PubMed
Rodriguez VI, Mammadova J, Permuth JB, Luthra A, Pena L, Friedman M, Dam A, Cappelle S, Malafa MP, Hallmon C, Miranda C, Mok SRS. Elevated Urinary Levels of Fungal and Environmental Toxins in Patients with Pancreatic Ductal Adenocarcinoma. J Gastrointest Cancer. 2024 Oct 17; 56(1):4.

View in: PubMed
Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, Ou FS, Dueck AC, Acoba J, Shergill A, Wolin EM, Halfdanarson TR, Konda B, Trikalinos NA, Tawfik B, Raj N, Shaheen S, Vijayvergia N, Dasari A, Strosberg JR, Kohn EC, Kulke MH, O'Reilly EM, Meyerhardt JA. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. N Engl J Med. 2025 Feb 13; 392(7):653-665.

View in: PubMed

People

Explore

Similar Concepts

Top Journals